GLP-1 receptor agonist
Liraglutide
Answer
Liraglutide is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 518 registered trials, 45 of them running. Brand names on the FDA label register: Liraglutide, Victoza, Xultophy 100/3.6 and Saxenda.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
518 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 138 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 316 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Liraglutide changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 518 trials
| NCT06836284 | The Evira Study: Additional Support During Obesity Treatment currently recruiting participants · register updated 2026-09-10 |
|---|---|
| NCT07787936 | GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry not yet recruiting participants · register updated 2026-08-26 |
| NCT05965908 | Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome completed · register updated 2026-08-25 |
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study running, but no longer enrolling · register updated 2026-08-13 |
| NCT03883412 | Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) currently recruiting participants · register updated 2026-08-12 |
| NCT05313529 | LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes completed · register updated 2026-08-06 |
| NCT06374875 | Fibrosis Lessens After Metabolic Surgery currently recruiting participants · register updated 2026-07-31 |
| NCT07225829 | A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthrit running, but no longer enrolling · register updated 2026-07-27 |
| NCT07702461 | Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists currently recruiting participants · register updated 2026-07-24 |
| NCT07225816 | Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stoma currently recruiting participants · register updated 2026-07-21 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.